4/A: Exagen Inc. CEO Amends Form 4 Filing to Correctly Report Stock Ownership
SEC Filing
John Aballi, President and CEO of Exagen Inc., files an amendment to a previous Form 4 to correct the number of directly and indirectly owned shares of common stock.
Summary
- John Aballi, the President and CEO of Exagen Inc., filed an amended Form 4 with the SEC.
- The amendment corrects an error in the original Form 4 filed on November 18, 2024, regarding the number of shares of common stock he directly and indirectly owns.
- The corrected filing indicates that Aballi directly owns 625,093 shares of common stock and indirectly owns 40,401 shares through his spouse.
Sentiment
Score: 7
Explanation: The document is a routine correction of a previous filing, indicating standard corporate governance procedures. There is no indication of positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report changes in their ownership of company stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The correction of the stock ownership information ensures accurate representation for shareholders.
Key Dates
| Date | Description |
|---|---|
| 11/14/2024 | Date of earliest transaction |
| 11/18/2024 | Date of original Form 4 filing that was amended |
| 02/25/2025 | Date of amended filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.